| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 25115 | 2017 |
| 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart … TA McDonagh, M Metra, M Adamo, RS Gardner, A Baumbach, M Böhm, ... European heart journal 42 (36), 3599-3726, 2021 | 9488 | 2021 |
| Dapagliflozin in patients with heart failure and reduced ejection fraction JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ... New England Journal of Medicine 381 (21), 1995-2008, 2019 | 5713 | 2019 |
| How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the … B Pieske, C Tschöpe, RA De Boer, AG Fraser, SD Anker, E Donal, ... European heart journal 40 (40), 3297-3317, 2019 | 1450 | 2019 |
| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ... New England Journal of Medicine 387 (12), 1089-1098, 2022 | 1253 | 2022 |
| 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology … AR Lyon, T López-Fernández, LS Couch, R Asteggiano, MC Aznar, ... European Heart Journal-Cardiovascular Imaging 23 (10), e333-e465, 2022 | 1185 | 2022 |
| Identification of seven loci affecting mean telomere length and their association with disease V Codd, CP Nelson, E Albrecht, M Mangino, J Deelen, JL Buxton, ... Nature genetics 45 (4), 422-427, 2013 | 970 | 2013 |
| Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction RA de Boer, DJA Lok, T Jaarsma, P van der Meer, AA Voors, HL Hillege, ... Annals of medicine 43 (1), 60-68, 2011 | 797 | 2011 |
| Galectin‐3: a novel mediator of heart failure development and progression RA de Boer, AA Voors, P Muntendam, WH van Gilst, DJ van Veldhuisen European journal of heart failure 11 (9), 811-817, 2009 | 793 | 2009 |
| Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association … PM Seferovic, P Ponikowski, SD Anker, J Bauersachs, O Chioncel, ... European journal of heart failure 21 (10), 1169-1186, 2019 | 722 | 2019 |
| Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND FP Brouwers, RA de Boer, P van der Harst, AA Voors, RT Gansevoort, ... European heart journal 34 (19), 1424-1431, 2013 | 666 | 2013 |
| Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology PM Seferović, MC Petrie, GS Filippatos, SD Anker, G Rosano, ... European journal of heart failure 20 (5), 853-872, 2018 | 650 | 2018 |
| Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations C Mueller, K McDonald, RA de Boer, A Maisel, JGF Cleland, ... European journal of heart failure 21 (6), 715-731, 2019 | 641 | 2019 |
| The ATLAS experiment at the CERN large hadron collider A Collaboration, G Aad, E Abat, J Abdallah, AA Abdelalim, A Abdesselam, ... Jinst 3, S08003, 2008 | 590 | 2008 |
| Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association SL Chow, AS Maisel, I Anand, B Bozkurt, RA De Boer, GM Felker, ... Circulation 135 (22), e1054-e1091, 2017 | 574 | 2017 |
| Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis L Yu, WPT Ruifrok, M Meissner, EM Bos, H Van Goor, B Sanjabi, ... Circulation: Heart Failure 6 (1), 107-117, 2013 | 543 | 2013 |
| Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C … AR Lyon, S Dent, S Stanway, H Earl, C Brezden‐Masley, A Cohen‐Solal, ... European journal of heart failure 22 (11), 1945-1960, 2020 | 511 | 2020 |
| The fibrosis marker galectin‐3 and outcome in the general population RA De Boer, DJ Van Veldhuisen, RT Gansevoort, AC Muller Kobold, ... Journal of internal medicine 272 (1), 55-64, 2012 | 493 | 2012 |
| New gene functions in megakaryopoiesis and platelet formation C Gieger, A Radhakrishnan, A Cvejic, W Tang, E Porcu, G Pistis, ... Nature 480 (7376), 201-208, 2011 | 478 | 2011 |
| Galectin-3 mediates aldosterone-induced vascular fibrosis L Calvier, M Miana, P Reboul, V Cachofeiro, E Martinez-Martinez, ... Arteriosclerosis, thrombosis, and vascular biology 33 (1), 67-75, 2013 | 465 | 2013 |
